Abacavir versus other nucleoside reverse transcriptase inhibitor (NRTI) backbone therapies for treatment of HIV infection

Documenti analoghi

• In Vitro Cross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations
  di: Li, Zhufang, et al.
  Pubblicazione: (2013)
• Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
  di: Torti, Carlo, et al.
  Pubblicazione: (2011)
• Ultra-Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse-Transcriptase Inhibitor (NRTI)–Treated Patients and NRTI-Naive Patients
  di: Margeridon-Thermet, Severine, et al.
  Pubblicazione: (2009)
• Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S
  di: Wang, Jiong, et al.
  Pubblicazione: (2013)
• Fetal consequences of maternal antiretroviral nucleoside reverse transcriptase inhibitor (NRTI) use in human and non-human primate pregnancy
  di: Poirier, Miriam C., et al.
  Pubblicazione: (2015)